SG Americas Securities LLC Sells 90,015 Shares of IQVIA Holdings Inc. $IQV

SG Americas Securities LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 78.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,045 shares of the medical research company’s stock after selling 90,015 shares during the quarter. SG Americas Securities LLC’s holdings in IQVIA were worth $4,567,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in IQV. Alliancebernstein L.P. boosted its holdings in shares of IQVIA by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA during the second quarter worth approximately $515,772,000. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares in the last quarter. Nordea Investment Management AB raised its position in IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the period. Finally, Lazard Asset Management LLC grew its stake in shares of IQVIA by 6.1% during the second quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock valued at $294,145,000 after buying an additional 107,500 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $242.70 on Monday. The company’s fifty day moving average price is $224.37 and its 200-day moving average price is $200.77. The stock has a market cap of $41.33 billion, a PE ratio of 33.29, a price-to-earnings-growth ratio of 2.47 and a beta of 1.36. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.05.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of analyst reports. BMO Capital Markets initiated coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and lifted their price target for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Finally, HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.19.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.